Yijia Liu is a prominent inventor based in Gaithersburg, MD (US), known for her significant contributions to the field of RNA interference (RNAi) therapeutics. With a total of six patents to her name, she has made remarkable strides in developing innovative treatments for various diseases, particularly those involving unwanted neovascularization.

Latest Patents

One of Yijia Liu's latest patents focuses on compositions and methods of RNAi therapeutics for the treatment of cancer and other neovascularization diseases. This invention provides treatments that control neovascularization (NV) through selective inhibition of pro-angiogenic biochemical pathways. It includes the inhibition of the VEGF pathway gene expression and localized inhibition at pathological NV tissues. The patent describes tissue-targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference. These nanoparticle compositions can be utilized alone or in combination with other therapeutic agents, such as VEGF pathway antagonists. The compositions and methods are applicable for treating NV diseases, including cancer, ocular disease, arthritis, and inflammatory diseases.

Career Highlights

Yijia Liu is currently associated with Intradigm Corporation, where she continues to advance her research and development efforts in RNAi therapeutics. Her work has garnered attention for its potential to revolutionize treatment options for patients suffering from various conditions related to neovascularization.

Collaborations

Yijia Liu has collaborated with notable colleagues, including Patrick Y Lu and Martin Woodle, to further enhance the impact of her research and innovations in the field.

Conclusion

Yijia Liu's contributions to RNAi therapeutics exemplify her dedication to advancing medical science and improving patient outcomes. Her innovative approaches to treating neovascularization diseases highlight the importance of research and collaboration in the field of biotechnology.